The normalisation of 'excessive' workforce drug testing?

In 'The normalization of 'sensible' recreational drug use' Parker, Williams and Aldridge (2002) present data on illegal drug use by adolescents and young adults in the UK. They argue that it is both widespread and largely socially benign - ie, normal. We contrast this 'normalisation' thesis with evidence of an increase in the introduction of drug policies - and drug testing - in British organisations. Such policies construct employee drug use as excessive enough to necessitate heightened management vigilance over workers, in order to preserve corporate interests. These contrasting representations of drug use inspire our discussion. We deploy the normal/ excessive couplet to unpick drug taking, to examine organisational drug policies and to comment upon emerging and potential resistance to these policies. Our contribution is to suggest that each of these activities can be understood as simultaneously normal and excessive, in an area where orthodox and critical analyses alike tend to be far more dualistic.

Workforce drug testing : a critique and reframing

This article aims to stimulate re-engagement with workforce drug testing as a current managerial technology emerging in UK organisations and not solely confined to the US. Drawing on sociological, labour process and wider organization studies literature, it reconceptualises assumptions about managerial ideology, employee agency and drug user’s subjectivity.

Zebrafish as a genetic model in pre-clinical drug testing and screening

The traditional drug discovery pipeline for the identification and development of compounds that selectively target specific molecules to ameliorate disease remains a major focus for medical research. However, the zebrafish is increasingly providing alternative strategies for various components of this pipeline. Zebrafish and their embryos are small, easily accessible and relatively low cost, making them applicable to high-throughput, small molecule screening. Zebrafish can also be manipulated by a range of forward and reverse genetics techniques to facilitate gene discovery and functional studies. Moreover, their physiological and developmental complexity provides accurate models of human disease to underpin mechanism of action and in vivo validation studies. Finally, several of these biological characteristics make zebrafish eminently suitable for toxicity testing, including eco-toxicology. Here we review the application of zebrafish to preclinical drug development and toxicity testing, including recent advances in mutant generation, drug screening and toxicology that serve to further enhance the capabilities of this valuable model organism in drug discovery.

The devil in high heels : drugs, symbolism and Kate Moss

This paper contributes to critical voices on the issue of organisational responses to employee drug use. It does so by exploring symbolic readings of organisations’ relations with drugs and drug-taking. Our focus is recent coverage of, and organisational responses to, the UK tabloid media’s exposé of fashion supermodel Kate Moss’s alleged cocaine use. We consider that the celebrity endorsement in this particular case highlights the ambiguities created by the symbolic associations between the organisation and the ‘image’ projected by the celebrity. Overall, we use this case to explore symbolic relationships between drugs, sex, femininity and organisation. Through highlighting these connections, we question further the rationality of organisational responses to employee drug use and, utilising Derrida’s (1981) extension of Plato’s notion of the pharmakon, consider whether workforce drug testing might be fruitfully seen as a symbolic mechanism for scapegoating and sacrifice in order to protect the organisation’s (masculine) moral order.

The devil in high heels : drugs, symbolism and Kate Moss

This paper contributes to critical voices on the issue of organisational responses to drugs and employee drug use. It does so by exploring some of the symbolism residing at the heart of organisations’ relations with drugs and drug taking. Our focus is recent media coverage of, and organisational responses to, the UK tabloid media’s exposé of fashion supermodel Kate Moss’s cocaine use. We use this case to explore symbolic relationships between drugs, sex and femininity, and organisation. Through highlighting these symbolic connections we question further the rationality of organisational responses to the ‘spectre’ of drugs and the issue of employee drug use. We conclude by suggesting that workforce drug testing regimes might be fruitfully seen as mechanisms for scapegoating and sacrifice in order to protect the organizational moral order.

Patron offending and intoxication in night time entertainment districts (POINTED) : a study protocol

Risky alcohol consumption is the subject of considerable community concern in Australia and internationally, particularly the risky drinking practices of young people consuming alcohol in the night-time economy. This study will determine some of the factors and correlates associated with alcohol-related risk-taking, offending and harm in and around licensed venues and night-time entertainment precincts across five Australian cities (three metropolitan and two regional). The primary aim of the study is to measure levels of pre-drinking, drinking in venues, intoxication, illicit drug use and potentially harmful drinking practices (such as mixing with energy drinks) of patrons in entertainment areas, and relating this to offending, risky behaviour and harms experienced. The study will also investigate the effects of license type, trading hours, duration of drinking episodes and geographical location on intoxication, offending, risk-taking and experience of harm. Data collection involves patron interviews (incorporating breathalysing and drug testing) with 7500 people attending licensed venues. Intensive venue observations (n=112) will also be undertaken in a range of venues, including pubs, bars and nightclubs. The information gathered through this study will inform prevention and enforcement approaches of policy makers, police and venue staff.

The importance of understanding motives for prescription substance use and misuse in sport

The use and misuse of prescription substances in the broader community, and among athletes in particular, is receiving increased attention, and one Australian sporting code is introducing testing for some of these substances. While testing in sport occurs in part to protect the health of the athlete, our responses to positive notifications are often punitive. Given that some prescription substances, such as opioids, are used to treat pain, and use has among athletes has been linked to pain sustained during sporting competition, understanding the prevalence and motivations of use among this group is important. Equally so is how the sporting community responds to this growing issue.

Rapid determination of carbohydrates in heroin drug seizures using capillary electrophoresis with short-end injection

A simple and rapid method for the analysis of carbohydrates in heroin samples by capillary electrophoresis utilizing a borate complexation method is described. Separations were performed using an uncoated fused silica capillary, 50 cm × 50 mm I.D. × 360 mm O.D. with an effective separation length of 9 cm. The system was run at 60°C with an applied voltage of -8 kilovolts. Injection of each sample was for 1 sec at -50 mbar. UV detection was employed with the wavelength set at 195 nm. The background electrolyte consisted of 65 mM borate, pH 12.0. Samples and standards were prepared in the run buffer containing 2 mg/mL of mannose as an internal standard. Under these conditions a test mixture containing glucose, sucrose, lactose, mannitol and mannose as an internal standard was resolved within 5 min. The method was used to determine the concentration of carbohydrates in heroin seizure samples and synthetic heroin samples. The results were in good agreement with the reported values.

The rapid analysis of heroin drug seizures using micellar electrokinetic chromatography with short-end injection

A simple and rapid method for the analysis of heroin seizures by micellar electrokinetic chromatography with short-end injection is described. Separations were performed using an uncoated fused silica capillary, 50 cm×50 mm I.D.×360 mm O.D. with an effective separation length of 8 cm. The system was run at 25°C with an applied negative voltage of –25 kilovolts. Injection of each sample was for 2 s at –50 mbar. UV detection was employed with the wavelength set at 210 nm. The background electrolyte consisted of 85:15 (water:acetonitrile, v/v) containing final concentrations of 25 mM SDS and 15 mM sodium borate, pH 9.5. Samples and standards were prepared in 0.1% v/v acetic acid and diluted in the run buffer containing 1 mg/ml of N,N-dimethyl-5-methoxytryptamine as an internal standard. Under these conditions a text mixture containing caffeine, paracetamol, morphine, codeine, heroin, and acetylcodeine was resolved within 1.5 min. The method was used to determine the concentration of heroin in heroin seizure samples, and the results were in good agreement with those obtained by a validated gas chromatographic method.

Markers and risk factors for HCV, HBV and HIV in a network of injecting drug users in Melbourne

Background and aims: Current injecting drug users (IDU) in major street drug markets within greater Melbourne were recruited to a longitudinal study on blood borne viruses. Here we investigated risk factors for hepatitis C virus (HCV), hepatitis B virus (HBV) and HIV infection in these IDU at the time of their recruitment.

Methods : Three hundred and eighty-two IDU completed detailed questionnaires on their drug use and risk behaviours, and provided blood samples for serology testing. These data were analysed using univariate and multivariate techniques.

Results : The overall prevalence of exposure to HCV, HBV and HIV was estimated at 70%, 34% and <1%, respectively. Independent predictors of HCV exposure were history of imprisonment (RR 1.34, 95% CI 1.19–1.52), use of someone else's needle or syringe (RR 1.23, 95% CI 1.07–1.42), >7.6 years length of time injecting (RR 1.21, 95% CI 1.07–1.37), and originating from Vietnam (RR 1.12, 95% CI 1.07–1.18). Independent predictors of HBV exposure were HCV exposure (RR 2.15, 95% CI 1.35–3.43), >7.6 years length of time injecting (RR 1.57, 95% CI 1.17–2.13) and originating from outside Australia (RR 1.60, 95% CI 1.22–2.10). Neither prison- nor community-applied tattoos predicted HCV or HBV exposure. Up to 31% of IDU who injected for 1 year or less were HCV antibody positive, as were 53% of those who injected for 2 years or less.

Conclusions : Ongoing engagement with young IDU, through the provision of harm reduction education and resources, is critical if we are to address blood borne viral infections and other health and social harms associated with injecting drug use.

Estimation and extrapolation of optimal treatment and testing strategies

We review recent developments in the estimation of an optimal treatment strategy or regime from longitudinal data collected in an observational study. We also propose novel methods for using the data obtained from an observational database in one health-care system to determine the optimal treatment regime for biologically similar subjects in a second health-care system when, for cultural, logistical, or financial reasons, the two health-care systems differ (and will continue to differ) in the frequency of, and reasons for, both laboratory tests and physician visits. Finally, we propose a novel method for estimating the optimal timing of expensive and/or painful diagnostic or prognostic tests. Diagnostic or prognostic tests are only useful in so far as they help a physician to determine the optimal dosing strategy, by providing information on both the current health state and the prognosis of a patient because, in contrast to drug therapies, these tests have no direct causal effect on disease progression. Our new method explicitly incorporates this no direct effect restriction.

Clinical association between pharmacogenomics and adverse drug reactions

Adverse drug reactions (ADRs) are a major public health concern and cause significant patient morbidity and mortality. Pharmacogenomics is the study of how genetic polymorphisms affect an individual’s response to pharmacotherapy at the level of a whole genome. This article updates our knowledge on how genetic polymorphisms of important genes alter the risk of ADR occurrence after an extensive literature search. To date, at least 244 pharmacogenes identified have been associated with ADRs of 176 clinically used drugs based on PharmGKB. At least 28 genes associated with the risk of ADRs have been listed by the Food and Drug Administration as pharmacogenomic biomarkers. With the availability of affordable and reliable testing tools, pharmacogenomics looks promising to predict, reduce, and minimize ADRs in selected populations.